S546
Clinical – Head & neck
ESTRO 2026
radiotherapy, 6 weeks and 3/6/12/18/24 months post radiotherapy. Secondary endpoints included longitudinal pattern of HR-QoL and formal comparisons between groups at 3/12/24 months post radiotherapy for HR-QoL subscales of interest (UW- QoL: physical, social-emotional function; MDADI: composite, global, emotional, functional, physical, EORTC QLQ-C30: global health, fatigue, appetite loss, financial difficulties, physical, role, emotional). Subscales were compared using multiple regression models adjusting for tumour (T) and nodal (N) stage, smoking status, chemotherapy received, baseline body mass index and baseline QoL subscale score. Testing was performed at the 1% significance level. Results: 205 participants with locally advanced OPSCC (48% T3/4, 21% N2(c)) were allocated to IMPT (n=136) or IMRT (n=69). UW-QoL, MDADI, and EORTC QLQ-C30 booklets at 3/12/24 months were all available for 175 (117 IMPT; 58 IMRT), 155 (100 IMPT; 55 IMRT) and 141 (98 IMPT; 43 IMRT) patients respectively, subject to completion of individual subscales. For completed questionnaires, individual subscales of interest had completion rates ranging from 97.3 to 99.9%. QoL generally worsened during radiotherapy then returned to near baseline levels by 12 months, with minimal changes afterwards (figure 1). Patterns of individual subscales were all consistent with this. There was no evidence of clinically significant differences in mean scores at 3/12/24 months for any subscales of UW- QoL, MDADI, and EORTC QLQ-C30 (table 1).
Conclusion: For locally advanced OPSCC, IMPT does not improve HR-QoL longitudinal outcomes compared with IMRT. The findings support the trial’s primary results. References: 1.Thomson D, Price J, Tyler M, Beasley MJ, Lester J, Nutting CM, Palaniappan N, Prestwich RJ, Shanmugasundaram R, Thompson A, Bulbeck H et al. Primary results for the phase III trial of Toxicity Reduction using Proton Beam Therapy for Oropharyngeal Cancer (TORPEdO; CRUK/18/010). International Journal of Radiation Oncology, Biology, Physics. 2025 Nov 15;123(4):1195-6. Keywords: Quality of life, proton beam therapy, head & neck Digital Poster 707 Evaluation of oral mucositis during chemoradiotherapy in head and neck cancer patients using a epigallocatechin gallate mouthwash Bianca Santo 1 , Donatella Russo 1 , Elisa Cavalera 1 , Paola De Franco 1 , Matteo Romanello 2 , Maria Cristina Barba 1 , Elisa Ciurlia 1 , Sara De Matteis 1 , Giuseppe Di Paola 1 , Angela Leone 1 , Antonella Papaleo 1 , Antonio Palumbo 2 , Angela Sardaro 1 1 Radiotherapy, "Vito Fazzi" Hospital, Lecce, Italy. 2 Otorhinolaryngology,Head and Neck Surgery, "Vito Fazzi" Hospital, Lecce, Italy Purpose/Objective: Concomitant chemoradiotherapy (CRT) for head and neck cancers frequently leads to oral mucositis and dysphagia, with potential impact on adherence, nutrition, and quality of life. To delineate the temporal behaviour of mucosal injury and its functional consequences, we prospectively monitored toxicity using complementary instruments. Material/Methods: Patients were assessed at baseline (T0), mid - treatment (T3), end of treatment (T6), and early follow - up (T9). Objective mucosal damage was quantified by the Oral Mucositis Assessment Scale (OMAS); clinician - graded severity by CTCAE; and swallowing - related function by the MDADI (Composite/Global as available). All patients followed a standardized supportive pathway
Made with FlippingBook - Share PDF online